Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $12.40.

A number of analysts recently weighed in on INO shares. Royal Bank of Canada decreased their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. HC Wainwright decreased their price target on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating on the stock in a research note on Monday, January 13th. Oppenheimer decreased their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, November 18th. Finally, JMP Securities restated a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th.

Institutional Trading of Inovio Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its position in Inovio Pharmaceuticals by 177.0% during the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 3,630 shares in the last quarter. Barclays PLC boosted its position in Inovio Pharmaceuticals by 15.0% during the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,111 shares in the last quarter. Geode Capital Management LLC boosted its position in Inovio Pharmaceuticals by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock worth $1,150,000 after purchasing an additional 6,874 shares in the last quarter. MetLife Investment Management LLC boosted its position in Inovio Pharmaceuticals by 129.1% during the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 8,546 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Inovio Pharmaceuticals by 6.4% during the fourth quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 13,269 shares in the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Trading Up 2.1 %

NASDAQ:INO opened at $1.98 on Friday. The firm has a market cap of $51.68 million, a P/E ratio of -0.94 and a beta of 0.89. The stock’s 50 day simple moving average is $2.02 and its 200-day simple moving average is $4.33. Inovio Pharmaceuticals has a 12-month low of $1.74 and a 12-month high of $14.75.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.